Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 19, 2020 - Issue 10
Submit an article Journal homepage
1,348
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editor

Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?

Emanuel RaschiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0487-7996View further author information
ORCID Icon,
Paolo CaraceniDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-1439-056XView further author information
ORCID Icon,
Elisabetta PoluzziDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyView further author information
&
Fabrizio De PontiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-0367-9595View further author information
ORCID Icon
Pages 1367-1369 | Received 04 Aug 2020, Accepted 11 Aug 2020, Published online: 25 Aug 2020

References

  • Peng L, Xiao K, Ottaviani S, et al. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;1–7. DOI:https://doi.org/10.1080/14740338.2020.1799975
  • Gatti M, Fusaroli M, Caraceni P, et al. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19 [published online ahead of print, 2020 Jul 8]. Br J Clin Pharmacol. 2020. DOI:https://doi.org/10.1111/bcp.14459
  • Jorgensen SCJ, Tse CLY, Burry L, et al. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19 [published online ahead of print, 2020 Jun 15]. Pharmacotherapy. 2020. DOI:https://doi.org/10.1002/phar.2438
  • Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):497–506.
  • Honda S, Harigai M. The safety of baricitinib in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2020;19(5):545–551.
  • Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–1573.
  • Verden A, Dimbil M, Kyle R, et al. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357–361.
  • Vallejo-Yagüe E, Weiler S, Micheroli R, et al. Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase [published online ahead of print, 2020 Jun 12]. Drug Saf. 2020. DOI:https://doi.org/10.1007/s40264-020-00958-9
  • Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19 [published online ahead of print, 2020 Jul 8]. Aliment Pharmacol Ther. 2020. DOI:https://doi.org/10.1111/apt.15916
  • Selmi C, De Santis M, Gershwin ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther. 2011;13(3):226.
  • Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4/6 inhibitors. Front Pharmacol. 2019 Oct 24;10: 1235.
  • Gatti M, Poluzzi E, De Ponti F, et al. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf. 2020. DOI:https://doi.org/10.1007/s40264-020-00975-8
  • Ai H, Chen W, Zhang L, et al. Predicting drug-induced liver injury using ensemble learning methods and molecular fingerprints. Toxicol Sci. 2018;165(1):100–107.
  • Veeravalli V, Dash RP, Thomas JA, et al. Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf. 2020;43(8):711–725.
  • Wang J, Bwayi M, Gee RRF, et al. PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches [published online ahead of print, 2020 Jun 16]. Expert Opin Drug Metab Toxicol. 2020;1–12. DOI:https://doi.org/10.1080/17425255.2020.1779701

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.